Study details
Enrolling now
Impact of Semaglutide on Tobacco Use and Related Health Behaviors
University of Oklahoma
NCT IDNCT06986993ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 4 years
Ages
18–65
Locations
1 site in OK
About this study
Researchers are testing whether semaglutide helps people quit smoking and improves their health. The trial will last 1460 days and involve 40 adults with obesity who smoke. Researchers will measure tobacco use, related behaviors, and biological markers of health.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Semaglutide
PhasePhase 4
DrugSemaglutide
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
semaglutide (GLP-1 agonist; stimulates insulin release)
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Weight